Brammer Bio Expands Leadership Team for Commercial Readiness


Brammer Bio Expands Leadership Team for Commercial Readiness

CAMBRIDGE, Mass., March 20, 2018 /PRNewswire/ -- Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the growth of the organization.

Doug Chambers joins Brammer as Vice President, Quality and Regulatory.  In addition to overseeing Quality for the company, Doug will be leading efforts to ensure Brammer operations are ready to deliver commercial viral vector products. Doug's recent experience includes readying a viral vector manufacturing facility for inspections by FDA and the EMA. He was previously in quality and compliance leadership roles at Millipore Sigma and Merck Research Laboratories.

Doug reports directly to Brammer's president and CEO, Mark Bamforth, who commented "Doug brings a wealth of relevant experience that will be key as Brammer works with regulators to set the compliance standards for the reliable supply of high quality viral vectors for cell and gene therapy products".

In addition, Dana Alexander joins Brammer as Site Head for Brammer's late phase and commercial viral vector manufacturing site in Cambridge, MA.  Dana brings twenty years of commercial manufacturing and operations expertise from his prior roles at Anika Therapeutics and Sanofi Genzyme.  Dana is leading the start-up and operations of the Kendall Square site which recently completed a transformation from a commercial protein biologics facility to a state-of-the-art viral vector production facility.

Larry Pitcher also joins Brammer as Site Head for its early-clinical development and viral vector manufacturing facilities in Alachua, FL. with around 200 skilled employees. Larry brings a decade of supply chain and operations experience from RTI Surgical, including roles as the managing director of the RTI German subsidiary, plus numerous accomplishments from his engagement in entrepreneurial businesses.

Chris Murphy, chief manufacturing officer of Brammer, commented, "We are excited to have Doug, Dana, and Larry join Brammer Bio in such important roles.  Their knowledge of operations and commercial experience are key ingredients to help Brammer meet the growing needs of our clients and the patients they serve.  Having these accomplished operations and quality leaders join Brammer is a demonstration of our commitment to ensure the consistent, high quality supply of viral vectors."

The Brammer team consists of over 350 extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients.  Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts.

About Brammer Bio

Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders and all employees. For more information, please visit

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Visit

Brammer Bio:
13859 Progress Boulevard
Alachua, FL 32615

250 Binney Street
Cambridge, MA 02142

Sales Enquiries: +1 866 GENE CMO (436 3266)

SOURCE Brammer Bio
Related Links